查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1990350

Dravet症候群市場：2026-2032年全球市場預測（依藥物類別、給藥途徑、病患年齡層、最終用戶和分銷管道分類）

Dravet Syndrome Market by Drug Class, Route Of Administration, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年 Dravet 症候群市場價值為 8.008 億美元，預計到 2026 年將成長至 8.6596 億美元，複合年成長率為 8.97%，到 2032 年將達到 14.5989 億美元。

主要市場統計數據
基準年 2025 8.008億美元
預計年份：2026年 8.6596億美元
預測年份：2032年 1,459,890,000 美元
複合年成長率 (%) 8.97%

全面而以臨床為基礎的德拉韋症候群介紹，重點關注診斷方面的進展、治療的複雜性以及醫療保健服務不斷變化的挑戰。

Dravet症候群是一種罕見的嚴重癲癇性腦病變，通常在嬰兒期發病，其特徵是長期、難治性癲癇發作和進行性神經發育障礙。臨床治療複雜，需要多學科協作，神經科醫生、急診科醫生、癲癇專科中心和家庭看護者之間必須密切配合。近年來，由於早期基因檢測和對該疾病表現型多樣性認知的提高，診斷準確率有所提高，但許多患者仍然飽受嚴重癲癇發作和嚴重合併症的困擾，存在未被滿足的醫療需求。

確定臨床、監管和數位領域中各種因素的整合，這些因素從根本上改變了 Dravet 症候群的治療管道、治療途徑和相關人員的優先事項。

圍繞德拉韋氏症候群的格局正在發生多方面的變革，這些變革正在重塑臨床治療、研究重點和商業策略。在臨床層面，早期基因診斷和以表現型為基礎的治療方法選擇使得更個人化的治療方案成為可能，而癲癇專科網路的成熟則集中了專業知識並改善了長期照護的協調性。同時，藥理學的進步正在豐富治療選擇，人們重新關注針對離子通道功能、GABA能調節和神經調節通道的不同類型藥物。

了解不斷變化的美國關稅政策對供應鏈、籌資策略以及獲得德拉韋症候群治療的途徑所產生的累積營運和商業影響。

到2025年，美國關稅趨勢將進一步增加德拉韋症候群相關產業鏈中製造商、經銷商和醫療保健機構的營運複雜性。影響進口藥品活性成分、某些醫療設備和包裝組件的關稅正在推高上游投入成本，迫使許多企業重新評估其供應鏈的韌性。擁有全球製造地的公司被迫評估其產品的總到岸成本，並考慮將關鍵生產流程轉移到國內或近岸地區，以降低貿易政策波動的風險。

整合藥物類別、醫療保健環境、分銷管道、給藥途徑和年齡層等臨床要求，可提供詳細的見解來指南您的策略。

細分市場分析揭示了不同藥物類別、終端使用者、分銷管道、給藥途徑和患者年齡層在臨床和商業性趨勢上的差異。在藥物類別細分方面，大麻素類藥物持續受到關注，其治療效果主要集中在大麻二酚和四氫大麻酚等次成分。同時，包括Clobazam、Diazepam和司替戊醇在內的GABA調變器在輔助性治療和搶救治療中繼續發揮核心作用。包括托吡酯類和丙戊酸在內的鈉通道阻斷劑對某些類型的癲癇仍然有效，這些藥物相對良好的安全性和耐受性指南醫生選擇藥物和聯合治療策略。

全面深入的臨床和商業性見解，涵蓋北美、南美、歐洲、中東、非洲和亞太地區的准入現實、監管差異和醫療保健基礎設施，並對區域差異提供細緻入微的見解。

區域趨勢對德拉韋症候群的臨床實踐、法規環境和商業性機會有顯著影響。在美洲，相關人員受益於成熟的專業醫療網路、先進的基因診斷基礎設施以及不斷發展的支付模式，這些模式越來越重視能夠證明臨床和功能顯著改善的證據。然而，醫療服務取得仍面臨挑戰，尤其是在農村和資源匱乏地區，這些地區專業的癲癇中心稀少，遠端保健的實施情況也因支付方政策而異。

策略商業環境分析重點闡述了大型製藥企業、創新生物技術公司、學術機構和服務供應商的綜合能力如何決定競爭地位。

Dravet症候群的生態系統涉及多種企業和機構活動，包括成熟的製藥公司、專業的生物技術公司、學術機構、契約製造組織（CMO）和專科藥房，各方發揮互補作用。老字型大小企業通常主導後期研發和大規模生產，擁有完善的商業基礎設施，能夠支援與支付方進行複雜的談判並建立廣泛的分銷網路。專業的生物技術公司則經常透過標靶作用機制和新型製劑推動創新，推動早期臨床治療方法，並透過策略合作拓展業務。

針對患有 Dravet 症候群的利害關係人的具體需求，提出切實可行且有影響力的產品開發、供應鏈最佳化和支付方參與建議。

行業領導者應推動一系列切實可行、以證據為基礎的舉措，將科學進步轉化為永續的患者獲益和商業性成功。首先，應優先考慮與監管機構和支付方進行早期且持續的合作，使證據生成與報銷要求相符，並製定能夠滿足兒童安全性和有效性終點的適應性開發計劃。其次，應投資於診斷基礎設施和基因檢測夥伴關係，以加速早期精準診斷，從而改善臨床試驗的患者招募，並在實際臨床實踐中選擇合適的治療標靶。

我們透過透明的混合方法調查方法，結合臨床證據審查、專家訪談和用例分析，產生可操作且檢驗的見解。

本分析的調查方法結合了嚴謹的證據整合和有針對性的相關人員參與，以確保其相關性和可靠性。主要資訊來源包括對同行評審的臨床文獻、監管指導文件和臨床實驗室註冊資訊進行系統性回顧，以了解治療機制、安全性概況和實驗室設計。次要資訊來源利用公開的政策文件、支付方相關文件、技術白皮書和臨床實踐指南，以闡明准入管道和臨床應用趨勢。此外，還對神經科、癲癇專家、專科藥劑師和衛生經濟學專家進行了訪談，以檢驗解釋性見解並識別文獻中未總是明確提及的實際考慮因素。

具有前瞻性的結論整合了臨床進展、營運挑戰以及為改善 Dravet 症候群患者的護理和就醫所必需的協作策略。

總之，應對德拉韋症候群複雜的臨床和商業性挑戰，需要在診斷、治療和醫療服務可近性等各個領域採取協調一致的方法。基因診斷技術的進步和治療手段的多樣化為改善癲癇控制和發育結果創造了新的機遇，但要實現這些益處，需要結構完善的循證策略、健全的價值鏈以及與支付方一致的價值證明。向遠端保健和以專科醫生為中心的醫療模式的轉變為擴大醫療服務可及性提供了途徑，但仍然存在差距，需要在地方和區域層面採取有針對性的干涉措施。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：德拉韋氏症候群市場：依藥物類別分類

  • 大麻素
    • CBD
    • THC
  • GABA調變器
    • Clobazam
    • Diazepam
    • 司替戊醇
  • 鈉通道阻斷劑
    • 托吡酯
    • 丙戊酸

第9章：德拉韋氏症候群藥物市場：依給藥途徑分類

  • 注射藥物
  • 鼻噴劑
  • 口服
  • 口腔黏膜
  • 經皮

第10章：德拉韋症候群市場：依患者年齡層別分類

  • 青年
  • 成人
  • 兒童
  • 嬰兒

第11章：德拉韋症候群市場：以最終用戶分類

  • 居家照護
  • 醫院
  • 癲癇專科中心

第12章：德拉韋氏症候群市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：德拉韋症候群市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：德拉韋氏症候群市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：德拉韋氏症候群市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國德拉韋症候群市場

第17章：中國的德拉韋氏症候群市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Biogen Inc.
  • Eisai Co., Ltd.
  • Encoded Therapeutics, Inc.
  • Epygenix Therapeutics, Inc.
  • GW Pharmaceuticals plc
  • Jazz Pharmaceuticals plc
  • Longboard Pharmaceuticals, Inc.
  • Marinus Pharmaceuticals, Inc.
  • Neuroelectrics BC
  • PTC Therapeutics, Inc.
  • Radiopharm Theranostics, LLC
  • Stoke Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • UCB SA
  • Zogenix, Inc.
Product Code: MRR-4D00F1312C81

The Dravet Syndrome Market was valued at USD 800.08 million in 2025 and is projected to grow to USD 865.96 million in 2026, with a CAGR of 8.97%, reaching USD 1,459.89 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 800.08 million
Estimated Year [2026] USD 865.96 million
Forecast Year [2032] USD 1,459.89 million
CAGR (%) 8.97%

A comprehensive and clinically grounded introduction to Dravet syndrome emphasizing diagnostic advances, therapeutic complexity, and evolving care delivery imperatives

Dravet syndrome represents a rare, severe epileptic encephalopathy with onset in infancy, characterized by prolonged, treatment-resistant seizures and progressive neurodevelopmental impairment. Clinical management is complex and multidisciplinary, requiring careful coordination between neurology, emergency medicine, specialty epilepsy centers, and home-based caregivers. Recent years have seen advances in diagnostic precision through earlier genetic testing and improved recognition of the condition's phenotypic heterogeneity, yet many patients continue to experience high seizure burden and profound comorbidities that drive unmet clinical needs.

This introduction frames the landscape in terms of evolving therapeutic modalities, care delivery shifts, and commercial implications. It emphasizes the interplay between novel pharmacologic strategies targeting specific pathophysiologic mechanisms, supportive and rescue interventions for acute events, and the critical role of specialized care settings. The narrative also highlights how payer policies, distribution pathways, and patient age segmentation shape access and adherence. By situating Dravet syndrome within contemporary clinical practice and policy trends, the section primes stakeholders to evaluate opportunities across drug classes, routes of administration, and care delivery innovations while remaining attuned to the ethical and regulatory complexities that accompany treatments for pediatric populations.

Identifying the convergent clinical, regulatory, and digital forces that are fundamentally transforming treatment pathways, therapy access, and stakeholder priorities in Dravet syndrome

The landscape for Dravet syndrome is shifting along multiple transformative vectors that are reshaping clinical care, research priorities, and commercial strategies. At the clinical level, earlier genetic diagnosis and phenotype-driven treatment selection are enabling more personalized therapeutic approaches, while the maturation of epilepsy specialty networks is concentrating expertise and improving longitudinal care coordination. Concurrently, advances in pharmacology have diversified the treatment palette, bringing renewed attention to distinct drug classes that target ion channel function, GABAergic modulation, and neuromodulatory pathways.

On the commercial front, digital health tools and telemedicine have expanded care touchpoints and facilitated remote monitoring, thereby altering traditional patterns of utilization across hospitals, specialty centers, and home care. Distribution channel innovation-spanning hospital pharmacies to specialty and online pharmacies-has reconfigured access pathways for high-cost therapies and acute rescue medications. At the same time, regulatory and reimbursement environments are evolving to address the specific needs of rare pediatric disorders, prompting manufacturers to prioritize evidence generation strategies that demonstrate both clinical benefit and real-world impact. Together, these shifts present a new set of opportunities and constraints for stakeholders seeking to advance therapeutic options while ensuring equitable access and sustainable reimbursement.

Understanding the cumulative operational and commercial consequences of evolving United States tariff policies on supply chains, procurement strategies, and access to Dravet syndrome therapies

In 2025, United States tariff dynamics have introduced an additional layer of operational complexity for manufacturers, distributors, and providers engaged in the Dravet syndrome ecosystem. Tariffs that affect imported active pharmaceutical ingredients, certain medical devices, and packaging components have increased upstream input costs and prompted many organizations to re-evaluate supply chain resilience. Firms with global manufacturing footprints have been compelled to assess the total landed cost of goods and to consider options for onshoring or nearshoring critical production steps to mitigate exposure to trade policy volatility.

These supply-side pressures interact with distribution practices in meaningful ways. Specialty pharmacies and hospital procurement groups are adapting contracting strategies to absorb or pass through incremental costs, with implications for inventory management, formulary placement negotiations, and patient out-of-pocket liability. Payers and integrated delivery networks are increasingly scrutinizing cost drivers and may demand enhanced pharmacoeconomic evidence or value-based contracting arrangements to justify coverage of higher-cost therapies. Additionally, tariff-induced changes in component sourcing have accelerated interest in manufacturing partnerships and consolidation among smaller biotechs that lack vertical integration. Overall, the cumulative effect of tariffs is to increase the importance of proactive supply chain planning, transparent cost modeling, and strategic engagement with procurement stakeholders to preserve access and commercial viability.

Deep segmentation-driven insights that synthesize drug class, care setting, distribution pathways, administration routes, and age-group specific clinical imperatives to guide strategy

Segmentation insights reveal differentiated clinical and commercial dynamics across drug classes, end users, distribution channels, routes of administration, and patient age groups. Within drug class segmentation, cannabinoids have garnered sustained interest with therapeutic activity concentrated in cannabidiol and tetrahydrocannabinol subcomponents, while GABA modulators encompass agents such as clobazam, diazepam, and stiripentol that remain central to adjunctive and rescue strategies. Sodium channel blockers, including agents like topiramate and valproate, continue to be relevant for certain seizure phenotypes, and the comparative safety and tolerability profiles of these classes inform prescriber choice and polytherapy strategies.

End user segmentation underscores distinct care delivery pathways: home care settings are increasingly important for long-term maintenance regimens and rescue medication administration, hospitals remain the locus for acute management and complex diagnostics, and specialty epilepsy centers provide concentrated expertise for refractory cases and surgical evaluations. Distribution channel segmentation shapes access modalities and patient experience, as hospital pharmacies, online pharmacies, retail pharmacies, and specialty pharmacies each present different operational and reimbursement interfaces that can affect initiation and continuity of therapy. Route of administration is another critical axis of differentiation; injectable and nasal routes are prioritized for rapid rescue intervention, oral and oromucosal forms support chronic management, and transdermal approaches are being explored for adherence and tolerability benefits. Patient age group segmentation highlights the spectrum of clinical needs across adolescents, adults, children, and infants, with infants and young children requiring tailored dosing, formulation considerations, and heightened safety monitoring. Integrating these segmentation lenses is essential for designing clinical development programs, market access strategies, and patient support services that align with real-world care pathways.

Regionally nuanced clinical and commercial insights that map access realities, regulatory differences, and care infrastructure across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a powerful influence on clinical practice, regulatory environments, and commercial opportunity for therapies addressing Dravet syndrome. In the Americas, stakeholders benefit from established specialty care networks, advanced genetic diagnostics infrastructure, and evolving payer models that are increasingly receptive to evidence demonstrating meaningful clinical and functional gains. Access challenges persist, however, particularly in rural and under-resourced communities where specialty epilepsy centers are scarce and telehealth adoption varies by payer policy.

Europe, Middle East & Africa presents a mosaic of regulatory frameworks and payer systems that require tailored market entry strategies; centralized approvals and national reimbursement negotiations can lead to divergent timelines and formulary outcomes across countries. Countries with strong rare disease programs and coordinated registries show faster uptake of innovative therapies, while others face infrastructure and funding constraints that limit access. Asia-Pacific is characterized by rapid adoption of diagnostic technologies in some markets and variable reimbursement pathways across others. Local manufacturing and procurement policies, as well as differing regulatory expectations for pediatric data, shape clinical adoption and commercial pathways. Across all regions, meaningful engagement with patient advocacy groups, investment in provider education, and alignment with local clinical guidelines remain critical to improving diagnosis, treatment initiation, and long-term management outcomes.

Strategic company landscape analysis highlighting how integrated capabilities across big pharma, biotech innovators, academic centers, and service providers determine competitive positioning

Corporate and institutional activity in the Dravet syndrome ecosystem reflects a mix of established pharmaceutical companies, specialty biotechs, academic centers, contract manufacturing organizations, and specialty pharmacies, each playing complementary roles. Established companies often drive late-stage development and large-scale manufacturing capacity, and they have the commercial infrastructure to support complex payer negotiations and broad distribution networks. Specialty biotechs contribute innovation through targeted mechanisms of action and novel formulations, frequently advancing therapies through earlier-phase trials and leveraging strategic partnerships to scale.

Academic medical centers and epilepsy clinics contribute critical real-world data, investigator-initiated studies, and natural history registries that inform both clinical development and health technology assessment. Contract manufacturing organizations and specialty pharmacies provide operational capabilities to manage orphan and pediatric product demands, including specialized compounding, cold chain logistics, and patient support services. Across this landscape, cross-sector collaboration is increasingly common, combining scientific expertise, clinical credibility, and distribution know-how to accelerate translation from bench to bedside. Companies that can integrate strong clinical evidence generation with sophisticated access strategies and robust patient support programs are positioned to lead in this therapeutic area.

Actionable, high-impact recommendations for product development, supply chain optimization, and payer engagement tailored to the unique demands of Dravet syndrome stakeholders

Industry leaders should pursue a set of pragmatic, evidence-focused actions to convert scientific advances into sustainable patient benefit and commercial success. First, prioritize early and continuous engagement with regulatory authorities and payers to align evidence generation with reimbursement requirements and to design adaptive development plans that accommodate pediatric safety and efficacy endpoints. Second, invest in diagnostic infrastructure and genetic testing partnerships to accelerate accurate early diagnosis, which in turn improves trial recruitment and real-world treatment targeting.

Third, reinforce supply chain resilience by diversifying sourcing of critical inputs, exploring nearshoring for selected manufacturing steps, and formalizing contingency plans to address tariff or trade disruptions. Fourth, develop differentiated distribution strategies that leverage specialty pharmacies for high-touch support, hospital pharmacies for acute care pathways, and online channels to reach geographically dispersed patient populations, with tailored adherence and education programs. Fifth, design age-appropriate formulations and administration routes that reflect the clinical realities of infants, children, adolescents, and adults, thereby enhancing tolerability and adherence. Finally, cultivate partnerships with specialty epilepsy centers and patient advocacy organizations to co-develop registries and real-world evidence initiatives that substantiate long-term outcomes and value, enabling more credible conversations with payers and health systems.

A transparent mixed-methods research methodology integrating clinical evidence review, expert interviews, and case study analysis to produce actionable and validated insights

The research methodology underpinning this analysis combines rigorous evidence synthesis with targeted stakeholder engagement to ensure relevance and credibility. Primary inputs include systematic review of peer-reviewed clinical literature, regulatory guidance documents, and clinical trial registries to capture therapeutic mechanisms, safety profiles, and trial designs. Secondary inputs draw on publicly available policy and payer documentation, technical white papers, and practice guidelines to contextualize access pathways and clinical adoption trends. Expert interviews with neurologists, epileptologists, specialty pharmacists, and health economics specialists were conducted to validate interpretive findings and to surface practical operational considerations not always explicit in the literature.

Qualitative thematic analysis and cross-validation of findings ensured consistency across data sources, while case study reviews of recent therapeutic launches provided real-world illustrations of commercialization challenges and successful strategies. The methodology emphasized transparency, with clear documentation of source types, interviewee roles, and analytical assumptions. Wherever possible, findings were triangulated across multiple sources to bolster reliability. This mixed-methods approach balances depth of clinical insight with practical commercial intelligence, providing stakeholders with actionable knowledge grounded in both evidence and frontline experience.

A forward-looking conclusion that synthesizes clinical progress, operational imperatives, and collaborative strategies necessary to improve care and access for Dravet syndrome patients

In conclusion, addressing the complex clinical and commercial challenges of Dravet syndrome requires coordinated efforts across diagnostic, therapeutic, and access domains. Advances in genetic diagnosis and diversifying therapeutic classes are creating new opportunities to improve seizure control and developmental trajectories, but realizing these benefits hinges on thoughtful evidence strategies, resilient supply chains, and payer-aligned value demonstration. Care delivery shifts toward telehealth and specialty-centric models offer avenues to expand access, yet disparities remain that demand targeted interventions at the regional and local levels.

Stakeholders who integrate precision diagnosis, age-appropriate formulation development, and robust patient support while engaging payers proactively will be best positioned to translate scientific progress into sustained clinical impact. Collaborative models that bring together industry, clinicians, and patient advocates to co-create registries and real-world evidence programs will strengthen the case for coverage and reimbursement. The path forward is pragmatic: combine scientific rigor with operational excellence and stakeholder alignment to deliver meaningful improvements for patients living with Dravet syndrome.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dravet Syndrome Market, by Drug Class

  • 8.1. Cannabinoids
    • 8.1.1. CBD
    • 8.1.2. THC
  • 8.2. Gaba Modulators
    • 8.2.1. Clobazam
    • 8.2.2. Diazepam
    • 8.2.3. Stiripentol
  • 8.3. Sodium Channel Blockers
    • 8.3.1. Topiramate
    • 8.3.2. Valproate

9. Dravet Syndrome Market, by Route Of Administration

  • 9.1. Injectable
  • 9.2. Nasal
  • 9.3. Oral
  • 9.4. Oromucosal
  • 9.5. Transdermal

10. Dravet Syndrome Market, by Patient Age Group

  • 10.1. Adolescents
  • 10.2. Adults
  • 10.3. Children
  • 10.4. Infants

11. Dravet Syndrome Market, by End User

  • 11.1. Home Care
  • 11.2. Hospital
  • 11.3. Specialty Epilepsy Centers

12. Dravet Syndrome Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Dravet Syndrome Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Dravet Syndrome Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Dravet Syndrome Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Dravet Syndrome Market

17. China Dravet Syndrome Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Biogen Inc.
  • 18.6. Eisai Co., Ltd.
  • 18.7. Encoded Therapeutics, Inc.
  • 18.8. Epygenix Therapeutics, Inc.
  • 18.9. GW Pharmaceuticals plc
  • 18.10. Jazz Pharmaceuticals plc
  • 18.11. Longboard Pharmaceuticals, Inc.
  • 18.12. Marinus Pharmaceuticals, Inc.
  • 18.13. Neuroelectrics BC
  • 18.14. PTC Therapeutics, Inc.
  • 18.15. Radiopharm Theranostics, LLC
  • 18.16. Stoke Therapeutics, Inc.
  • 18.17. Takeda Pharmaceutical Company Limited
  • 18.18. UCB S.A.
  • 18.19. Zogenix, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRAVET SYNDROME MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRAVET SYNDROME MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DRAVET SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DRAVET SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. GCC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GCC DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. GCC DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 171. GCC DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 172. GCC DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 173. GCC DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. GCC DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GCC DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. GCC DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. G7 DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. G7 DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. G7 DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 198. G7 DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 199. G7 DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 200. G7 DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. G7 DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. G7 DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. G7 DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. NATO DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. NATO DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. NATO DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 207. NATO DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 208. NATO DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 209. NATO DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. NATO DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. NATO DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. NATO DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES DRAVET SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA DRAVET SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)